George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- July15 2004
- Volume 11
- Issue 13
Shopping for Car Insurance
Author(s)Michael Sheehan
Advertisement
Tip:
Auto insurance rates are finallyheading down after nearly 4 years ofgoing nowhere but up. Some car ownersare in line to get premium cuts of upto 10%, but industry watchers say thegoodies are going to a favored few (ie,those with an excellent driving recordand a clean credit history). Delving intocredit records is a new tool for carinsurers looking to cut risk. They citestatistics that show a poor credit recordis related to a higher risk of accidents. The selective premium cuts are creatinga wide price spread betweeninsurance carriers. If you're a good risk,shopping for car insurance at Web siteslike www.insweb.com or www.insurance.com may save you hundreds ofdollars on your car insurance.
Articles in this issue
about 18 years ago
Batten Down Your Inheritance Hatchesabout 18 years ago
Decide What to Do with Your IRA Assetsabout 18 years ago
Start Your Retirement Plan Immediatelyabout 18 years ago
Know when Less Is More and More Is Lessabout 18 years ago
Ease Worries of the Sandwich Generationabout 18 years ago
Uncover the Fine Print on Annuitiesabout 18 years ago
Impart Memories Before They Are Goneabout 18 years ago
Rent Real Estate as an Investment Optionabout 18 years ago
Find the Right Mortgage Lender for Youabout 18 years ago
Renovate Without Building Property TaxAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5